BioRender 图标

Pericyte (cross-section, dying 2)

Pericyte (cross-section,  dying 2) - Editable icon of a cross-sectional view of a dying pericyte icon
[{"image":"https://icons.cdn.biorender.com/w75xh75/63651d626b73320021b586c9/63628eed99665a0021bbba60.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/63651d626b73320021b586c9/63628eed99665a0021bbba60.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/63651d626b73320021b586c8/63628eed99665a0021bbba60.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/63651d626b73320021b586c8/63628eed99665a0021bbba60.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/63651d626b73320021b586c7/63628eed99665a0021bbba60.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/63651d626b73320021b586c7/63628eed99665a0021bbba60.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/63651d626b73320021b586c6/63628eed99665a0021bbba60.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/63651d626b73320021b586c6/63628eed99665a0021bbba60.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/63651d626b73320021b586c5/63628eed99665a0021bbba60.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/63651d626b73320021b586c5/63628eed99665a0021bbba60.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/63651d626b73320021b586c4/63628eed99665a0021bbba60.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/63651d626b73320021b586c4/63628eed99665a0021bbba60.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/63651d626b73320021b586c3/63628eed99665a0021bbba60.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/63651d626b73320021b586c3/63628eed99665a0021bbba60.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/63651d626b73320021b586c2/63628eed99665a0021bbba60.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/63651d626b73320021b586c2/63628eed99665a0021bbba60.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/63651d626b73320021b586c1/63628eed99665a0021bbba60.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/63651d626b73320021b586c1/63628eed99665a0021bbba60.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/63651d626b73320021b586c0/63628eed99665a0021bbba60.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/63651d626b73320021b586c0/63628eed99665a0021bbba60.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/63651d626b73320021b586bf/63628eed99665a0021bbba60.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/63651d626b73320021b586bf/63628eed99665a0021bbba60.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/63651d626b73320021b586be/63628eed99665a0021bbba60.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/63651d626b73320021b586be/63628eed99665a0021bbba60.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/63651d626b73320021b586bd/63628eed99665a0021bbba60.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/63651d626b73320021b586bd/63628eed99665a0021bbba60.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/63651d626b73320021b586bc/63628eed99665a0021bbba60.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/63651d626b73320021b586bc/63628eed99665a0021bbba60.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/63651d626b73320021b586bb/63628eed99665a0021bbba60.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/63651d626b73320021b586bb/63628eed99665a0021bbba60.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/63651d626b73320021b586ba/63628eed99665a0021bbba60.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/63651d626b73320021b586ba/63628eed99665a0021bbba60.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/63651d626b73320021b586b9/63628eed99665a0021bbba60.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/63651d626b73320021b586b9/63628eed99665a0021bbba60.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/63651d626b73320021b586b8/63628eed99665a0021bbba60.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/63651d626b73320021b586b8/63628eed99665a0021bbba60.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/63651d626b73320021b586b7/63628eed99665a0021bbba60.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/63651d626b73320021b586b7/63628eed99665a0021bbba60.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/63651d626b73320021b586b6/63628eed99665a0021bbba60.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/63651d626b73320021b586b6/63628eed99665a0021bbba60.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/63651d626b73320021b586b5/63628eed99665a0021bbba60.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/63651d626b73320021b586b5/63628eed99665a0021bbba60.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/63651d626b73320021b586b4/63628eed99665a0021bbba60.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/63651d626b73320021b586b4/63628eed99665a0021bbba60.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/63651d626b73320021b586b3/63628eed99665a0021bbba60.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/63651d626b73320021b586b3/63628eed99665a0021bbba60.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/63651d626b73320021b586b2/63628eed99665a0021bbba60.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/63651d626b73320021b586b2/63628eed99665a0021bbba60.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/63651d626b73320021b586b1/63628eed99665a0021bbba60.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/63651d626b73320021b586b1/63628eed99665a0021bbba60.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/63651d626b73320021b586b0/63628eed99665a0021bbba60.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/63651d626b73320021b586b0/63628eed99665a0021bbba60.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/63651d626b73320021b586af/63628eed99665a0021bbba60.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/63651d626b73320021b586af/63628eed99665a0021bbba60.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/63651d626b73320021b586ae/63628eed99665a0021bbba60.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/63651d626b73320021b586ae/63628eed99665a0021bbba60.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/63651d626b73320021b586ad/63628eed99665a0021bbba60.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/63651d626b73320021b586ad/63628eed99665a0021bbba60.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/63651d626b73320021b586ac/63628eed99665a0021bbba60.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/63651d626b73320021b586ac/63628eed99665a0021bbba60.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/63651d626b73320021b586ab/63628eed99665a0021bbba60.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/63651d626b73320021b586ab/63628eed99665a0021bbba60.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/63651d626b73320021b586aa/63628eed99665a0021bbba60.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/63651d626b73320021b586aa/63628eed99665a0021bbba60.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/63651d626b73320021b586a9/63628eed99665a0021bbba60.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/63651d626b73320021b586a9/63628eed99665a0021bbba60.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/63651d626b73320021b586a8/63628eed99665a0021bbba60.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/63651d626b73320021b586a8/63628eed99665a0021bbba60.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/63651d626b73320021b586a7/63628eed99665a0021bbba60.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/63651d626b73320021b586a7/63628eed99665a0021bbba60.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/63651d626b73320021b586a6/63628eed99665a0021bbba60.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/63651d626b73320021b586a6/63628eed99665a0021bbba60.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/63651d626b73320021b586a5/63628eed99665a0021bbba60.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/63651d626b73320021b586a5/63628eed99665a0021bbba60.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/63651d626b73320021b586a4/63628eed99665a0021bbba60.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/63651d626b73320021b586a4/63628eed99665a0021bbba60.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/63651d626b73320021b586a3/63628eed99665a0021bbba60.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/63651d626b73320021b586a3/63628eed99665a0021bbba60.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/63651d626b73320021b586a2/63628eed99665a0021bbba60.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/63651d626b73320021b586a2/63628eed99665a0021bbba60.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/63651d626b73320021b586a1/63628eed99665a0021bbba60.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/63651d626b73320021b586a1/63628eed99665a0021bbba60.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/63651d626b73320021b586a0/63628eed99665a0021bbba60.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/63651d626b73320021b586a0/63628eed99665a0021bbba60.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/63651d626b73320021b5869f/63628eed99665a0021bbba60.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/63651d626b73320021b5869f/63628eed99665a0021bbba60.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/63651d626b73320021b5869e/63628eed99665a0021bbba60.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/63651d626b73320021b5869e/63628eed99665a0021bbba60.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/63651d626b73320021b5869d/63628eed99665a0021bbba60.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/63651d626b73320021b5869d/63628eed99665a0021bbba60.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/63651d626b73320021b5869c/63628eed99665a0021bbba60.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/63651d626b73320021b5869c/63628eed99665a0021bbba60.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/63651d626b73320021b5869b/63628eed99665a0021bbba60.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/63651d626b73320021b5869b/63628eed99665a0021bbba60.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/63651d626b73320021b5869a/63628eed99665a0021bbba60.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/63651d626b73320021b5869a/63628eed99665a0021bbba60.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/63651d626b73320021b58699/63628eed99665a0021bbba60.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/63651d626b73320021b58699/63628eed99665a0021bbba60.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/63651d626b73320021b58698/63628eed99665a0021bbba60.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/63651d626b73320021b58698/63628eed99665a0021bbba60.png"}]
使用此图标 – 免费
注册无需信用卡。

此图标可在 BioRender 中完全编辑

  • 添加文本、形状及其他图标
  • 搜索 50,000 多种科学准确的图标
  • 重新着色并重新排列每一个图标、线条和标签
  • 导出或分享以满足任何使用需求
Scientist Avatars

加入 400 多万名科学家 的行列,制作可直接用于发表的图表

从图标到成品图表,只需几分钟

  • 搜索 来自 50,000 多个科学准确、经同行评审的图标
  • 自定义 添加标签、形状和更多图标——一切皆可完全编辑
  • 导出 或与协作者分享您的图表
    ‍

图标不合适?探索更多内容。

搜索涵盖 30 多个生命科学领域的 50,000 多个图标。

search icon
arrow-right
pericyte,rouget,endothelium,endothelia,epithelial,epithelium,endothelial,cell,mural,microcirculation,BBB,leaky BBB,blood brain barrier,blood,vessel,contractile,dying,dead,degrade,degradation,die,compromised,necrosis,necrotic,cell death,damaged,disintegrate,disintegration
查看更多

尝试使用同义词,或注册以在应用中请求图标。

图像类型

Pericyte (cross-section, dying 2) icon JPEG

Pericyte (cross-section, dying 2) icon PNG

Pericyte (cross-section, dying 2) icon SVG

Pericyte (cross-section, dying 2) icon GIF

BioRender 图标常见问题解答

How are scientists using the Pericyte (cross-section, dying 2) icon in their work?

BioRender users often use the Pericyte (cross-section, dying 2) icon in posters, grant applications, educational materials, and graphical abstracts. It’s especially useful for projects involving Cell Types.

我可以在 BioRender 图表或科学插图中使用此图标吗?

Yes, the Pericyte (cross-section, dying 2) is fully integrated into BioRender’s drag-and-drop platform. You can easily add it to any scientific figure, workflow, or poster, whether you’re building from scratch or starting with a BioRender template.

Is the Pericyte (cross-section, dying 2) icon customizable in BioRender?

Most icons in BioRender, including the Pericyte (cross-section, dying 2) icon, are customizable. You can adjust icon size, colors, and positioning, and add custom labels to tailor the design to your specific research context.

Can I export figures that include the Pericyte (cross-section, dying 2) icon for publication or presentations?

Yes, figures containing the Pericyte (cross-section, dying 2) icon can be exported in multiple formats, including PNG, JPG, PDF, and SVG. High-resolution and vector exports are available on paid plans, making them ideal for journals, slide decks, and print materials.

How do I cite BioRender if I use this icon?

Unlock publication permissions with a paid plan, and include 'Created with BioRender.com' in your figure legend, or cite BioRender directly per your journal's guidelines.

Is the Pericyte (cross-section, dying 2) icon used in BioRender templates or poster layouts?

Many BioRender templates include icons like the Pericyte (cross-section, dying 2) icon — especially those focused on Cell Types. You can search BioRender’s template library or add this icon manually to any canvas.

什么是 BioRender?

BioRender is a web‑based software that helps you create scientific figures in minutes. Use this Pericyte (cross-section, dying 2) icon along with our library of more than 30,000 life science icons.

在 BioRender 中使用此图标

立即开始制作专业的科学图表
antibody elements3D Phospholipid illustration

正在寻找科学内容?

浏览超过 5 万个经同行评审、易于使用且免费的图标和模板。

立即寻找您的专属素材
x icon